Articles by Daniel Marsh
AMC Faces Dilution Risk Despite Record Weekend from Toy Story 5
AMC shares dipped to $2.79 after Toy Story 5 drove its busiest U.S. weekend of 2026, but recent $150 million share sales and dilution warnings weigh on investors.
Dow Rises on Caterpillar, Visa Gains; Nasdaq Slips on Tech Weakness
The Dow Jones rose 214 points, lifted by Caterpillar and Visa, as U.S.-Iran talks progress eased oil and inflation fears, while the Nasdaq slipped.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
Definium Shares Surge on LSD-Based Depression Drug Trial Success
DFTX shares soared 64.2% premarket after Definium's Phase 3 Emerge trial showed DT120 achieved an 8.1-point placebo-adjusted benefit in major depressive disorder.
CRH to Acquire Arcosa in $8.5B Cash Deal, Boosting US Infrastructure and Energy Exposure
CRH will acquire Arcosa for $150 per share in cash, valuing the company at $8.5 billion and expanding its U.S. infrastructure and energy transmission footprint.
Yum Brands Sells Pizza Hut in $2.7B Deal to Streamline Portfolio
Yum Brands is selling Pizza Hut in a $2.7 billion split deal to LongRange Capital and Yum China, as U.S. same-store sales decline for the tenth consecutive quarter.
Creator Ad Spending to Hit $44 Billion in 2026 as Brands Seek Performance-Based Deals
U.S. creator ad spending is set to hit $44 billion in 2026 as brands shift to longer, performance-based partnerships. However, 79% of marketers struggle with ROI measurement.
Jersey Mike’s Topples Chick-fil-A in Customer Satisfaction Rankings
Jersey Mike’s scored 84 in the 2026 American Customer Satisfaction Index, edging Chick-fil-A’s 83 to end its 11-year reign as top QSR, as value and digital pickup gain importance.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
Getty Images Surges on OpenAI Deal, Financial Details Remain Under Wraps
Getty Images (GETY) saw its stock jump 167% premarket after revealing a multi-year partnership with OpenAI to display licensed images in ChatGPT, but financial terms were not disclosed.
Russell Reconstitution Set to Drive SpaceX Stock More Than Geopolitical Tensions
SpaceX (SPCX) joins the Russell 1000 on Friday, with JPMorgan estimating $4 billion in passive demand, potentially overshadowing geopolitical news from Iran.